Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025

Kura Oncology, Inc.

2024-Q2 EPS reported -$1.18

Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.
Cash, equivalents & short-term investments $491.5M at June 30, 2024; runway into 2027.
Ziftomenib completed enrollment of 85 patients in KOMET-001 pivotal trial; FDA Breakthrough Therapy Designation; topline data early 2025.
Phase 1b expansion of KOMET-007 (ziftomenib + ven/aza and 7+3) now enrolling; data expected Q4 2024.
IND cleared for ziftomenib in GIST; proof-of-concept study with imatinib planned H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.